Acadia Pharmaceuticals develops and commercialises therapies for neurological and rare diseases, focusing on conditions that have historically attracted limited industry attention. Founded in 1993 and headquartered in San Diego, California, the company operates across North America, Europe and beyond. Its technical expertise spans neuroscience therapeutics, receptor pharmacology, clinical development in neurology and psychiatry, and rare disease drug development.
The company has achieved notable regulatory milestones. NUPLAZID® is the first and only FDA-approved treatment for hallucinations and delusions associated with Parkinson's disease psychosis. DAYBUE® represents the first therapy approved for Rett syndrome, a rare neurodevelopmental disorder. These approvals reflect Acadia's focus on conditions where unmet medical needs remain substantial.
Acadia's clinical pipeline includes programmes targeting Alzheimer's disease psychosis, Lewy body dementia psychosis, and rare genetic neurodevelopmental diseases. The company works with strategic partners including Stoke Therapeutics, Neuren Pharmaceuticals and Vanderbilt University to advance its research and development efforts across these therapeutic areas.
